HASHIMOTO’S
THYROIDITIS
      Dr. Sangita
CASE
 48 yrs; Female
 Midline neck swelling,painless & diffuse,
  gradually increasing in size x2mths
 Fatigue, depression, constipation, wt gain,
  cold intolerance, dry &coarse hair and
  skin.
PROPOSED INVESTIGATIONS
   Family history
   FNAC
   Thyroid Function tests- mainly TSH (early
    stages-T3,T4normal)
   Thyroid antibody
   Thyroid scan
   Ultrasound
   Normal thyroid tissue
    with follicles filled with
    colloid .
   Thyroid cells form
    follicles, spheres of
    epithelial cells (always
    single-layered in
    health, usually more-or-
    less cuboidal, variably
    tall or short).
   The C-cells
    (parafollicular cells) of
    the thyroid are visible
    between the follicles

NORMAL THYROID
Iodine transport
   Na+/I- symport
    protein controls
    serum I- uptake
   Based on Na+/K+
    antiport potential

   Stimulated by
    TSH
   Inhibited by
    Perchlorate
   Thyroid Peroxidase (TPO)
    ◦ Apical membrane protein
    ◦ Catalyzes Iodine organification to tyrosine
      residues of thyroglobulin
    ◦ Antagonized by methimazole, PTU

   Iodine coupled to Thyroglobulin
    ◦ Monoiodotyrosine (Tg + one I-)
    ◦ Diiodotyrosine (Tg + two I-)

   Pre-hormones secreted into follicular
    space


Thyroid hormone formation
Thyroid Hormone Control
   Produced by Hypothalamus
   Release is pulsatile, circadian
   Downregulated by T3
   Travels through portal venous system to
    adenohypophysis
   Stimulates TSH formation




TRH
   Produced by Adenohypophysis
    Thyrotrophs
   Upregulated by TRH
   Downregulated by T4, T3
   Travels through portal venous system to
    cavernous sinus, body.
   Stimulates several processes
    ◦ Iodine uptake
    ◦ Colloid endocytosis
    ◦ Growth of thyroid gland



TSH
   Majority of circulating hormone is T4
    ◦   98.5% T4
    ◦   1.5% T3

   Total Hormone load is influenced by serum
    binding proteins
    ◦   Albumin 15%
    ◦   Thyroid Binding Globulin 70%
    ◦   Transthyretin 10%

   Regulation is based on the free component of
    thyroid hormone




Thyroid Hormone
   TRH
   TSH
   Total T3, T4
   Free T3, T4
   RAIU
   Thyroglobulin
   Antibodies: Anti-TPO, Anti-TSHr



Thyroid Evaluation
Thyroid Evaluation
   Scintillation counter measures radioactivity after
    I123 administration.
   Uptake varies greatly by iodine status
    ◦ Indigenous diet (normal uptake 10% vs. 90%)
    ◦ Amiodarone, Contrast study, Topical betadine
   Elevated RAIU with hyperthyroid symptoms
    ◦ Graves’
    ◦ Toxic goiter
   Low RAIU with hyperthyroid symptoms
    ◦ Thyroiditis (Subacute, Active Hashimoto’s)
    ◦ Hormone ingestion (Thyrotoxicosis factitia, Hamburger
      Thyrotoxicosis)
    ◦ Excess I- intake in Graves’ (Jod-Basedow effect)
    ◦ Ectopic thyroid carcinoma (Struma ovarii)




RAIU
AUTOIMMUNE
HYPOTHYROIDISM
   SYMPTOMS- tiredness;weakness;dry skin;
    feeling cold; hair loss; difficulty concentrating
    and poor memory;constipation; wt gain with
    poor apetite; dyspnea; hoarse voice;
    menstrual irregularities;paraesthesia;
    impaired healing.

   SIGNS- dry coarse skin, cool peripheral
    extremities; puffy face,hands and feet;diffuse
    alopecia; bradycardia; peripheral
    edema;delayed tendon reflex
    relaxation;carpal tunnel syndrome; serous
    cavity effusions.
   Agenesis
   Thyroid destruction
    ◦   Hashimoto’s thyroiditis
    ◦   Surgery
    ◦   I131 ablation
    ◦   Infiltrative diseases
    ◦   Post-laryngectomy
   Inhibition of function
    ◦ Iodine deficiency
    ◦ Iodine administration
    ◦ Anti-thyroid medications (PTU, Methimazole, Lithium,
      Interferon)
    ◦ Inherited defects
   Transient
    ◦ Postpartum
    ◦ Thyroiditis




Hypothyroidism
Hypothyroidism
    Cause is determined by geography
     ◦   Hashimoto’s in industrialized countries
     ◦   May be due to iodine excess in some costal
         areas
    Diagnosis
     ◦   Low FT4, High TSH (Primary, check for
         antibodies)
     ◦   Low FT4, Low TSH (Secondary or Tertiary, TRH
         stimulation test, MRI)
    Treatment
     ◦   Levothyroxine (T4) due to longer half life
     ◦   Treatment prevents bone loss, cardiomyopathy,
         myxedema
Hashimoto’s
(Chronic, Lymphocytic)

   Most common cause of hypothyroidism
   Result of antibodies to TPO, TBG
   Commonly presents in females 30-50 yrs.
   Usually non-tender and asymptomatic
   Lab values
    ◦   High TSH
    ◦   Low T4
    ◦   Anti-TPO Ab
    ◦   Anti-TBG Ab
   Treat with Levothyroxine
   Most common cause of goiter and hypothyroidism in the U.S.
   Physical
    ◦ Painless diffuse goiter
   Lab studies
    ◦   Hypothyroidism
    ◦   Anti TPO antibodies (90%)
    ◦   Anti Thyroglobulin antibodies (20-50%)
    ◦   Acute Hyperthyroidism (5%)
   Treatment
    ◦ Levothyroxine if hypothyroid
    ◦ Triiodothyronine (for myxedema coma)
    ◦ Thyroid suppression (levothyroxine) to decrease goiter size
       Contraindications
       Stop therapy if no resolution noted
    ◦ Surgery for compression or pain.




Hashimoto’s Thyroiditis
 Includes goitrous thyroiditis (hashimoto’s
  thyroiditis & Atrophic thyroiditis)
 Symptoms range fm subclinical to overt
  hypothyroidism.




AUTOIMMUNE
HYPOTHYROIDISM
 PREVALENCE - 4/1000 women; 1/1000
  men.
 Japanese population, genetic factors,
  chronic exposure to high iodine diet.
 Mean age at diagnosis 60yrs, prevalence
  of hypothyroidism increases with age.
 A/ka Autoimmune thyroiditis & struma
  lymphomatosa.
 Age & Gender: 45-65 years of age, more
  common in women than in man, with a
  female predominance of 10:1 to 20:1.
 Symptoms and signs: euthyroidism or
  hypothyroidism.
   Sensitization of autoreactive CD4+ T-helper cells to thyroid
    antigens appears to be the initiating event. The effector
    mechanisms for thyrocyte death include the following:
     ◦ CD8+ cytotoxic T cell-mediated cell death: CD8+
       cytotoxic T cells may cause thyrocyte destruction by one
       of two pathways: exocytosis of perforin/granzyme
       granules or engagement of death receptors, specifically
       CD95 (also known as Fas) on the target cell
     ◦ Cytokine-mediated cell death: CD4+ T cells produce
       inflammatory cytokines such as IFN-γ in the immediate
       thyrocyte milieu, with resultant recruitment and
       activation of macrophages and damage to follicles.
     ◦ Binding of antithyroid antibodies (anti-TSH receptor
       antibodies, antithyroglobulin, and antithyroid peroxidase
       antibodies) followed by antibody-dependent cell-
       mediated cytotoxicity (ADCC)




PATHOGENESIS
Pathogenesis
   The goiter is generally symmetrical, often
    with a conspicuous pyramidal lobe.
    Grossly, the tissue involved by
    Hashimoto's thyroiditis is pinkish-tan to
    frankly yellowish and tends to have a
    rubbery firmness. The capsular surface is
    gently lobulated and non-adherent to
    peri-thyroid structures.
 Symmetric enlargement with tan yellow
  cut surface.
 Intact capsule.
Coexistent nodular hyperplasia
   Microscopically, there is a diffuse process
    consisting of a combination of epithelial cell
    destruction, lymphoid cellular infiltration, and
    fibrosis.
    The thyroid cells tend to be slightly larger
    and assume an acidophilic staining character;
    they are then called Hurthle or Askanazy cells
    and are packed with mitochondria.
   The follicular spaces shrink, and colloid is
    absent or sparse. Fibrosis may be completely
    absent or present in degrees ranging from
    slight to moderate;
   In children, oxyphilia and fibrosis are less
    prominent, and hyperplasia of epithelial cells
    may be marked.
In 1912 ,Hashimoto
                      described four patients
                      with a chronic disorder
                      of the thyroid, which he
                      termed struma
                      lymphomatosa. The
                      thyroid glands of these
                      patients were
                      characterized by diffuse
                      lymphocytic infiltration,
                      fibrosis, parenchymal
                      atrophy, and an
Dr Hakaru Hashimoto   eosinophilic change in
                      some of the acinar
                      cells.
EM- Deposits of dense material representing
IgG are found along the basement membrane
on electron microscopy
MANAGEMENT
   No cure or way to know the time duration
    till how much the disease will last.
   Thyroid replacement medications.
   In patients with Hashimoto’s thyroiditis and
    a large goiter, thyrotropin-suppressing
    doses of levothyroxine sodium can be given
    over the short term (i.e., six months) to
    decrease the size of the goiter.
    In most patients with Hashimoto’s
    thyroiditis (whether euthyroid or
    hypothyroid), goiter size will decrease by
    30% aftr 6 mths of therapy with
    levothyroxine sodium
   Thank you for your attention.




The End

Hashimoto’s thyroiditis

  • 1.
  • 2.
    CASE  48 yrs;Female  Midline neck swelling,painless & diffuse, gradually increasing in size x2mths  Fatigue, depression, constipation, wt gain, cold intolerance, dry &coarse hair and skin.
  • 3.
    PROPOSED INVESTIGATIONS  Family history  FNAC  Thyroid Function tests- mainly TSH (early stages-T3,T4normal)  Thyroid antibody  Thyroid scan  Ultrasound
  • 4.
    Normal thyroid tissue with follicles filled with colloid .  Thyroid cells form follicles, spheres of epithelial cells (always single-layered in health, usually more-or- less cuboidal, variably tall or short).  The C-cells (parafollicular cells) of the thyroid are visible between the follicles NORMAL THYROID
  • 5.
    Iodine transport  Na+/I- symport protein controls serum I- uptake  Based on Na+/K+ antiport potential  Stimulated by TSH  Inhibited by Perchlorate
  • 6.
    Thyroid Peroxidase (TPO) ◦ Apical membrane protein ◦ Catalyzes Iodine organification to tyrosine residues of thyroglobulin ◦ Antagonized by methimazole, PTU  Iodine coupled to Thyroglobulin ◦ Monoiodotyrosine (Tg + one I-) ◦ Diiodotyrosine (Tg + two I-)  Pre-hormones secreted into follicular space Thyroid hormone formation
  • 8.
  • 9.
    Produced by Hypothalamus  Release is pulsatile, circadian  Downregulated by T3  Travels through portal venous system to adenohypophysis  Stimulates TSH formation TRH
  • 10.
    Produced by Adenohypophysis Thyrotrophs  Upregulated by TRH  Downregulated by T4, T3  Travels through portal venous system to cavernous sinus, body.  Stimulates several processes ◦ Iodine uptake ◦ Colloid endocytosis ◦ Growth of thyroid gland TSH
  • 11.
    Majority of circulating hormone is T4 ◦ 98.5% T4 ◦ 1.5% T3  Total Hormone load is influenced by serum binding proteins ◦ Albumin 15% ◦ Thyroid Binding Globulin 70% ◦ Transthyretin 10%  Regulation is based on the free component of thyroid hormone Thyroid Hormone
  • 12.
    TRH  TSH  Total T3, T4  Free T3, T4  RAIU  Thyroglobulin  Antibodies: Anti-TPO, Anti-TSHr Thyroid Evaluation
  • 13.
  • 14.
    Scintillation counter measures radioactivity after I123 administration.  Uptake varies greatly by iodine status ◦ Indigenous diet (normal uptake 10% vs. 90%) ◦ Amiodarone, Contrast study, Topical betadine  Elevated RAIU with hyperthyroid symptoms ◦ Graves’ ◦ Toxic goiter  Low RAIU with hyperthyroid symptoms ◦ Thyroiditis (Subacute, Active Hashimoto’s) ◦ Hormone ingestion (Thyrotoxicosis factitia, Hamburger Thyrotoxicosis) ◦ Excess I- intake in Graves’ (Jod-Basedow effect) ◦ Ectopic thyroid carcinoma (Struma ovarii) RAIU
  • 15.
  • 16.
    SYMPTOMS- tiredness;weakness;dry skin; feeling cold; hair loss; difficulty concentrating and poor memory;constipation; wt gain with poor apetite; dyspnea; hoarse voice; menstrual irregularities;paraesthesia; impaired healing.  SIGNS- dry coarse skin, cool peripheral extremities; puffy face,hands and feet;diffuse alopecia; bradycardia; peripheral edema;delayed tendon reflex relaxation;carpal tunnel syndrome; serous cavity effusions.
  • 18.
    Agenesis  Thyroid destruction ◦ Hashimoto’s thyroiditis ◦ Surgery ◦ I131 ablation ◦ Infiltrative diseases ◦ Post-laryngectomy  Inhibition of function ◦ Iodine deficiency ◦ Iodine administration ◦ Anti-thyroid medications (PTU, Methimazole, Lithium, Interferon) ◦ Inherited defects  Transient ◦ Postpartum ◦ Thyroiditis Hypothyroidism
  • 19.
    Hypothyroidism  Cause is determined by geography ◦ Hashimoto’s in industrialized countries ◦ May be due to iodine excess in some costal areas  Diagnosis ◦ Low FT4, High TSH (Primary, check for antibodies) ◦ Low FT4, Low TSH (Secondary or Tertiary, TRH stimulation test, MRI)  Treatment ◦ Levothyroxine (T4) due to longer half life ◦ Treatment prevents bone loss, cardiomyopathy, myxedema
  • 20.
    Hashimoto’s (Chronic, Lymphocytic)  Most common cause of hypothyroidism  Result of antibodies to TPO, TBG  Commonly presents in females 30-50 yrs.  Usually non-tender and asymptomatic  Lab values ◦ High TSH ◦ Low T4 ◦ Anti-TPO Ab ◦ Anti-TBG Ab  Treat with Levothyroxine
  • 21.
    Most common cause of goiter and hypothyroidism in the U.S.  Physical ◦ Painless diffuse goiter  Lab studies ◦ Hypothyroidism ◦ Anti TPO antibodies (90%) ◦ Anti Thyroglobulin antibodies (20-50%) ◦ Acute Hyperthyroidism (5%)  Treatment ◦ Levothyroxine if hypothyroid ◦ Triiodothyronine (for myxedema coma) ◦ Thyroid suppression (levothyroxine) to decrease goiter size  Contraindications  Stop therapy if no resolution noted ◦ Surgery for compression or pain. Hashimoto’s Thyroiditis
  • 22.
     Includes goitrousthyroiditis (hashimoto’s thyroiditis & Atrophic thyroiditis)  Symptoms range fm subclinical to overt hypothyroidism. AUTOIMMUNE HYPOTHYROIDISM
  • 23.
     PREVALENCE -4/1000 women; 1/1000 men.  Japanese population, genetic factors, chronic exposure to high iodine diet.  Mean age at diagnosis 60yrs, prevalence of hypothyroidism increases with age.
  • 24.
     A/ka Autoimmunethyroiditis & struma lymphomatosa.  Age & Gender: 45-65 years of age, more common in women than in man, with a female predominance of 10:1 to 20:1.  Symptoms and signs: euthyroidism or hypothyroidism.
  • 25.
    Sensitization of autoreactive CD4+ T-helper cells to thyroid antigens appears to be the initiating event. The effector mechanisms for thyrocyte death include the following: ◦ CD8+ cytotoxic T cell-mediated cell death: CD8+ cytotoxic T cells may cause thyrocyte destruction by one of two pathways: exocytosis of perforin/granzyme granules or engagement of death receptors, specifically CD95 (also known as Fas) on the target cell ◦ Cytokine-mediated cell death: CD4+ T cells produce inflammatory cytokines such as IFN-γ in the immediate thyrocyte milieu, with resultant recruitment and activation of macrophages and damage to follicles. ◦ Binding of antithyroid antibodies (anti-TSH receptor antibodies, antithyroglobulin, and antithyroid peroxidase antibodies) followed by antibody-dependent cell- mediated cytotoxicity (ADCC) PATHOGENESIS
  • 26.
  • 27.
    The goiter is generally symmetrical, often with a conspicuous pyramidal lobe. Grossly, the tissue involved by Hashimoto's thyroiditis is pinkish-tan to frankly yellowish and tends to have a rubbery firmness. The capsular surface is gently lobulated and non-adherent to peri-thyroid structures.
  • 28.
     Symmetric enlargementwith tan yellow cut surface.  Intact capsule.
  • 29.
  • 30.
    Microscopically, there is a diffuse process consisting of a combination of epithelial cell destruction, lymphoid cellular infiltration, and fibrosis.  The thyroid cells tend to be slightly larger and assume an acidophilic staining character; they are then called Hurthle or Askanazy cells and are packed with mitochondria.  The follicular spaces shrink, and colloid is absent or sparse. Fibrosis may be completely absent or present in degrees ranging from slight to moderate;  In children, oxyphilia and fibrosis are less prominent, and hyperplasia of epithelial cells may be marked.
  • 35.
    In 1912 ,Hashimoto described four patients with a chronic disorder of the thyroid, which he termed struma lymphomatosa. The thyroid glands of these patients were characterized by diffuse lymphocytic infiltration, fibrosis, parenchymal atrophy, and an Dr Hakaru Hashimoto eosinophilic change in some of the acinar cells.
  • 36.
    EM- Deposits ofdense material representing IgG are found along the basement membrane on electron microscopy
  • 37.
    MANAGEMENT  No cure or way to know the time duration till how much the disease will last.  Thyroid replacement medications.  In patients with Hashimoto’s thyroiditis and a large goiter, thyrotropin-suppressing doses of levothyroxine sodium can be given over the short term (i.e., six months) to decrease the size of the goiter.  In most patients with Hashimoto’s thyroiditis (whether euthyroid or hypothyroid), goiter size will decrease by 30% aftr 6 mths of therapy with levothyroxine sodium
  • 38.
    Thank you for your attention. The End